An announcement from Zevra Therapeutics ( (ZVRA) ) is now available.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zevra Therapeutics has announced the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick Disease Type C (NPC). This breakthrough offers a new hope for patients, as it is used in combination with miglustat to treat neurological symptoms in both adults and children. Zevra’s patient support program, AmplifyAssist™, provides essential resources to navigate prescription processes and insurance challenges, ensuring patients can access this life-changing therapy.
See more data about ZVRA stock on TipRanks’ Stock Analysis page.
